9 completed, 2 unknown. 7 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 5, Unknown 2 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
Follow PHARMENTERPRISES LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of XC243 in Patients With Exacerbation of Chronic Cystitis XC243 25 mg, XC243 50 mg, XC243 75 mg - Cystitis | Phase 2 | Unknown | PHARMENTERPRISES LLC | 280 | 2024-04-01 | 2024-04-30 |
| Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Doses of XC243 After Single and Multiple Oral Administration in Healthy Volunteers. XC243 50 mg single, XC243 100 mg single, Placebo single - Healthy Volunteers | Phase 1 | Completed | PHARMENTERPRISES LLC | 38 | 2022-09-28 | 2023-11-18 |
| Study to Assess Efficacy and Safety of Treamid for Patients With Reduced Exercise Tolerance After COVID-19 Treamid, Treamid twice a day, Treamid once a day - SARS-CoV-2 Infection, Lung Fibrosis | Phase 2 / Phase 3 | Unknown | PHARMENTERPRISES LLC | 412 | 2022-08-01 | 2022-08-25 |
| Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia Treamid, Placebo - SARS-CoV-2 Infection, Fibrosis Lung | Phase 2 | Completed | PHARMENTERPRISES LLC | 60 | 2020-09-01 | 2021-04-05 |
| Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI XC221, Placebo - Influenza, Acute Respiratory Viral Infections | Phase 2 | Completed | PHARMENTERPRISES LLC | 120 | 2019-01-31 | 2020-11-16 |
| Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections XC221 100 mg, XC221 200 mg, Placebo - Acute Respiratory Viral Infections, Influenza | Phase 2 | Completed | PHARMENTERPRISES LLC | 120 | 2018-02-12 | 2019-11-04 |
| Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers XC221 60 mg, XC221 200 mg, Placebo - Influenza, Acute Respiratory Infection | Phase 1 | Completed | PHARMENTERPRISES LLC | 32 | 2017-05-22 | 2018-03-08 |
| XC8 in the Treatment of Patients With Bronchial Asthma XC8 Oral Tablet, Placebo Oral Tablet - Bronchial Asthma | Phase 2 | Completed | PHARMENTERPRISES LLC | 120 | 2016-09-20 | 2018-03-01 |
| XC8 in the Treatment of Patients With Acute Respiratory Viral Infection XC8 20 mg, XC8 100 mg, XC8 200 mg - Influenza, Acute Respiratory Infection | Phase 2 / Phase 3 | Completed | PHARMENTERPRISES LLC | 320 | 2016-02-03 | 2018-02-23 |
| Study to Assess Safety, Tolerability and Pharmacokinetics of Treamid in Healthy Volunteers Treamid 5 mg, Treamid 15 mg, Treamid 50 mg - Metabolic Syndrome | Phase 1 | Completed | PHARMENTERPRISES LLC | 20 | 2016-01-25 | 2020-06-17 |
| XC8 Safety, Tolerability and Pharmacokinetics in Healthy Volunteers XC8, Placebo - Asthma | Phase 1 | Completed | PHARMENTERPRISES LLC | 28 | 2015-02-14 | 2018-02-22 |
Influenza, Human (4) · Asthma (2) · COVID-19 (2) · Pulmonary Fibrosis (2) · Coronavirus Infections (1) · Cystitis (1) · Metabolic Syndrome (1)
N,N'-bis(2-(1H-imidazol-2-yl)ethyl)pentanediamide (3) · XC221 (3) · histamine glutarimide (2) · Single Person (1)
Russia (9)
Elena A Smolyarchuk, MD, PhD (1)